Becton, Dickinson and Company reports its fiscal third-quarter results on August 6 with the stock recovering sharply — up 9.4% over the past month to $165.62 — yet still nursing a 14% year-to-date decline that keeps the debate wide open.
Options positioning reflects growing confidence rather than fear ahead of the print. The put/call ratio has dropped to 0.52, running below its 20-day average of 0.57 and sitting well off the 1.0 highs reached earlier in the year. That shift in options flow aligns with the price recovery: over the past two weeks, the PCR fell from the mid-0.60s range to its current low, tracking BDX's rally almost step-for-step. Borrow conditions add little tension to the setup — availability is deep at 867%, meaning shares to lend far outnumber those already borrowed, and cost-to-borrow has edged up to 0.54% but remains firmly in low territory.
Short interest tells a more cautious sub-story worth watching. Bears have added exposure meaningfully: SI has climbed roughly 78% from early June levels to 3.7% of free float — still not extreme, but the pace of accumulation in six weeks is notable. The short score has been drifting higher all month, reaching 40.9 on July 30. That's not a crowded short by any measure, but it signals that a subset of investors is actively fading the recent rally.
The analyst community is broadly constructive, though targets are dispersed. UBS initiated coverage with a Buy rating and a $190 target just last week — the freshest signal and a meaningful endorsement at a premium to the current price. Evercore trimmed its target to $180 in early July while keeping an Outperform, reflecting cautiousness on execution rather than a change in direction. The bear case centres on margin uncertainty: FY2026 operating margin guidance came in below Street expectations, and the post-separation structure — BDX spun off its Biosciences & Diagnostics divisions into a joint venture with Waters — leaves investors without the full historical earnings baseline for comparison. Bulls counter that the separation sharpens BDX's focus on high-growth MedTech markets, management has committed to ~30% operating margins over time, and the 12-month forward EPS growth rank sits at the 87th percentile of the universe. The two most recent quarterly prints each produced a positive day-one reaction of around 3%, though both faded over the following five sessions.
Invesco materially built its position to 3.2% of shares, a notable institutional add. BlackRock increased its stake as well, to 9.5% of shares outstanding. On the insider side, CEO Tom Polen sold roughly $2.95 million in shares on June 1 — the only C-suite trade in the window — though the size relative to the company is modest and the trades carry low significance scores.
Thursday's print is ultimately a test of whether BDX's restructured business can deliver the margin trajectory management has promised, and whether the 9% monthly rally has gotten ahead of that evidence.
See the live data behind this article on ORTEX.
Open BDX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
